Pharmaceutical

MSD’s Welireg secures FDA approval for renal cell carcinoma

This is the second FDA approval for MSD’s HIF-2α inhibitor following a 2021 approval to treat von Hippel-Lindau disease.

Dec 16, 2023 - 18:00
MSD’s Welireg secures FDA approval for renal cell carcinoma
This is the second FDA approval for MSD’s HIF-2α inhibitor following a 2021 approval to treat von Hippel-Lindau disease.
Read the original article

Tags:

Previous Article

Biden shakes up US drug pricing landscape with inflation-related penalties 

Next Article

Biovac receives IFC loan for vaccine manufacturing in Africa

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AI will severely impact almost a fifth of jobs, Indeed says

AI will severely impact almost a fifth of jobs, Indeed ...

Oct 21, 2023

Boehringer reinforces interest in NASH with new $2bn deal  

Boehringer reinforces interest in NASH with new $2bn de...

Jan 3, 2024

How rising stars in science and medicine think about mentorship and bouncing back from rejection

How rising stars in science and medicine think about me...

Oct 18, 2023